Data & ReproClinical MedicineFreedomIntelligence/OpenClaw-Medical-SkillsData & Reproduction

tooluniverse-clinical-trial-design

Maintainer FreedomIntelligence · Last updated April 1, 2026

Strategic clinical trial design feasibility assessment using ToolUniverse. Evaluates patient population sizing, biomarker prevalence, endpoint selection, comparator analysis, safety monitoring, and regulatory pathways. Creates comprehensive feasibility reports with evidence grading, enrollment projections, and trial design recommendations. Use when planning Phase 1/2 trials, assessing trial feasibility, or designing….

OpenClawNanoClawAnalysisReproductiontooluniverse-clinical-trial-design🏥 medical & clinicalmedical toolsstrategic

Original source

FreedomIntelligence/OpenClaw-Medical-Skills

https://github.com/FreedomIntelligence/OpenClaw-Medical-Skills/tree/main/skills/tooluniverse-clinical-trial-design

Maintainer: FreedomIntelligence
License: MIT
Last updated: April 1, 2026

Skill Snapshot

Key Details From SKILL.md

2 min

Key Notes

Systematically assess clinical trial feasibility by analyzing 6 research dimensions. Produces comprehensive feasibility reports with quantitative enrollment projections, endpoint recommendations, and regulatory pathway analysis.
IMPORTANT: Always use English terms in tool calls (drug names, disease names, biomarker names), even if the user writes in another language. Only try original-language terms as a fallback if English returns no results. Respond in the user's language.
indication = "EGFR-mutant non-small cell lung cancer" biomarker = "EGFR L858R.

Source Doc

Excerpt From SKILL.md

1. Report-First Approach (MANDATORY)

DO NOT show tool outputs to user. Instead:

Create [INDICATION]_trial_feasibility_report.md FIRST
Initialize with all section headers
Progressively update as data arrives
Present only the final report

2. Evidence Grading System

Grade	Symbol	Criteria	Examples
A	★★★	Regulatory acceptance, multiple precedents	FDA-approved endpoint in same indication
B	★★☆	Clinical validation, single precedent	Phase 3 trial in related indication
C	★☆☆	Preclinical or exploratory	Phase 1 use, biomarker validation ongoing
D	☆☆☆	Proposed, no validation	Novel endpoint, no precedent

3. Feasibility Score (0-100)

Weighted composite score:

Patient Availability (30%): Population size × biomarker prevalence × geography
Endpoint Precedent (25%): Historical use, regulatory acceptance
Regulatory Clarity (20%): Pathway defined, precedents exist
Comparator Feasibility (15%): Standard of care availability
Safety Monitoring (10%): Known risks, monitoring established